BNGO - バイオナノ・ジェノミクス （Bionano Genomics Inc.）

EF Hutton has initiated coverage of Bionano Genomics Inc (NASDAQ: BNGO ) with a Buy rating and a price target of $1.75 . The analyst says Bionano Genomics''s optical genome mapping (OGM) platform is well-positioned to disrupt cytogenetic analysis with its ability to reliably and efficiently detect Structural Variants (SV) across a comprehensive range of resolutions that existing techniques do not. BNGO targets a global market of 10,000 cytogenetic labs that analyze roughly 10 million DNA samples yearly in BNGO''s … Full story available on Benzinga.com

https://www.investing.com/news/pro/bionano-genomics-receives-investment-bank-analyst-rating-update-3090863

High-risk penny stocks have long tempted investors with the potential for significant returns. However, it is crucial to acknowledge the inherent risks associated with these speculative investments. If you’re investing in high-risk penny stocks, prepare for an exhilarating journey. It’s crucial to acknowledge the inherent risks involved in these speculative investments. This article will focus on three high-risk penny stocks with the potential for significant wealth accumulation. If you’re attracted to the allure of penny stocks, it’s vital to approach them with caution and conduct thorough research. While some penny stocks may present exciting growth prospects, others are filled with uncertainties and risks. ME 23andMe $2.04 BNGO Bionano Genomics $0.68 PGEN Precigen $1.24 23andMe Holding Company (ME) Source: nevodka / Shutterstock.com 23andMe (NASDAQ: ME ), a prominent genetic testing services company, has embarked on expansion endeavors. However, these initiatives have not been well-received by shareholders.

Everyone who invests in growth stocks hopes that one of their holdings will become the next Netflix (NASDAQ: NFLX ), the next Amazon (NASDAQ: AMZN ), or the next Facebook. In other words, they’re looking for names that can transform, or disrupt, entire sectors. I believe that in the current era, which features several truly transformative technologies — such as artificial intelligence, the Internet of Things, and improved renewable-energy systems — it’s easier than ever to find disruptive growth stock winners. Here are three growth stocks that are disrupting their industries. Because of these companies’ disruptive offerings, their stocks should soar over the longer term. And since the Street has frowned on most growth stocks for nearly two years, these names, along with many other of the best disruptive growth stock picks, are trading at very low valuations. Bionano (BNGO) Source: Dennis Diatel / Shutterstock.com Bionano’s (NASDAQ: BNGO ) optical genome mapping system, Saphyr, has consistently shown, in many studies, its ability to identify significantly more structural variations in DNA than standard tools.

https://www.investing.com/news/pro/bionano-genomics-receives-investment-bank-analyst-rating-update-3080232

This is a classic matchup of a grizzled top dog against a scrappy competitor.

SAN DIEGO, May 01, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), today announced that on May 1, 2023, it published an open letter to stockholders in support of its proposals at its upcoming annual meeting of stockholders, a copy of which is included at the end of this press release. Details of the Annual Meeting of Stockholders The annual meeting of stockholders will be held virtually, via live webcast at www.virtualshareholdermeeting.com/BNGO2023 , on June 14, 2023, at 10:00 a.m. Pacific Time. Stockholders of record as of April 24, 2023, may vote at the annual meeting or by proxy over the telephone, through the internet or using the Notice of Internet Availability of Proxy Materials mailed to such stockholders. Stockholders may change their vote at any time before the final vote at the annual meeting. Details regarding voting procedures are included in the Company''s proxy statement for the annual meeting, filed with the U.S. Securities and Exchange Commission on April 28, 2023.

SAN DIEGO, May 01, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), today announced that on May 1, 2023, it published an open letter to stockholders in support of its proposals at its upcoming annual meeting of stockholders, a copy of which is included at the end of this press release. Details of the Annual Meeting of Stockholders The annual meeting of stockholders

Sooner or later, investors will stop fearing the “phantom recession,” i.e. the recession that really doesn’t exist except in many economists’ imaginations. At that point, many growth stocks should come soaring back. The latest evidence supporting my “phantom recession” theory came last week, when S&P reported that the U.S. private sector Purchasing Managers’ Index for April came in at 53.5 in April, up from 52.8 in March. Moreover, the nation’s Services PMI rose to 53.7, well above analysts’ average estimate of 51.5. Since services generate the lion’s share of U.S. economic output and the line between expansion and contraction among PMI stands at 50, the 53.7 reading indicates that the American economy is actually quite strong. That being said, and believing growth stocks will benefit from “phantom recession” realizations, here are some top stocks to consider. EVGO EVgo $5.80 BB BlackBerry $3.95 BNGO BioNano Genomics $0.74 CDNS Cadence Design Systems $203.40 ARRY Array Technologies $21.00 SCHW Charles Schwab $51.29 GM General Motors $32.93 EVgo ( EVGO ) Source: Sundry Photography / Shutterstock.com Electric vehicle charging company EVgo (NASDAQ: EVGO ) just reported a blowout fourth quarter.

The life sciences company said it expects another improved quarter of revenue.

Currently, Bionano Genomics Inc.’s (BNGO) stock is trading at $1.92, marking a gain of 5.19% from last night’s close. At this price, the stock is -55.75% below its 52-week high of $4.35 and 65.95% above its 52-week low of $1.16. Based on the past 30-day period, the stock price is -4.29% below the high and […]

During the last session, Bionano Genomics Inc. (NASDAQ:BNGO)’s traded shares were 6.34 million, with the beta value of the company hitting 2.26. At the end of the trading day, the stock’s price was $1.70, reflecting an intraday loss of -7.10% or -$0.13. The 52-week high for the BNGO share is $4.35, that puts it down … After Bionano Genomics Inc. (NASDAQ: BNGO) Surges -605.88% From Highs, What Will It Look Like? Read More »

Bionano Genomics (BNGO) is collaborating with Nvidia (NVDA) to develop an acceleration platform for use in Bionano''s optical genome mapping ((OGM)) workflow.The collaboration is…

SAN DIEGO, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a collaboration with NVIDIA to develop an acceleration platform for use in Bionano’s optical genome mapping (OGM) workflow. This collaboration is expected to significantly improve data processing speed while reducing time and cost associated with secondary analysis of OGM data. The computation platform is designed to enable a small laboratory and information technology footprint, which would allow for rapid decentralized deployment.

Source: Spyro the Dragon/Shutterstock.com Fans of Jaguar Health (NASDAQ: JAGX ) stock will want to keep an eye on the company tomorrow as it prepares for an investor webcast . Investors will want to tune into that webcast as it will cover topics relevant to the company. That includes going over the unmet need associated with cancer therapy-related diarrhea (CTD). Breast cancer oncologist Lee Schwartzberg, MD, FACP, will discuss the topic. In addition to that, another topic of discussion will be Jaguar Health’s mental health Entheogen Therapeutics Initiative (ETI). This has it planning to discover novel, therapeutic opportunities derived from psychoactive plants. National Geographic Explorer-in-Residence Wade Davis, PhD, will cover this topic. The investor webcast is set to take place at 10:30 a.m. Eastern Time on Jan. 12, 2023. Investors that want to check out the webcast can register and participate by following this link . Other JAGX Stock News Today Jaguar Health also announced that Sandra M.